Optimizing Barrett’s Endoscopy Quality to Reduce Missed Neoplasia : FG | May 2026

Introduction

Barrett's Esophagus is the principal precursor lesion for Esophageal Adenocarcinoma. Surveillance endoscopy aims to detect dysplasia and early neoplasia at a curable stage; however, post-endoscopy upper gastrointestinal cancers remain a significant problem. Contemporary UK data suggest particularly high rates of missed neoplasia in Barrett’s surveillance compared with upper gastrointestinal endoscopy overall, emphasizing the urgent need for improved examination quality.

Problem Statement

Despite widespread Barrett’s surveillance programs, substantial rates of missed dysplasia and early cancer persist, largely due to variability in endoscopic examination quality, lesion recognition and adherence to optimal imaging and biopsy protocols.

Summary

This video review provides a practical and clinically focused framework for improving the quality of Barrett’s endoscopy, emphasizing meticulous mucosal inspection, advanced imaging utilization and standardized biopsy techniques to enhance neoplasia detection.

The review begins by reinforcing the importance of accurate endoscopic landmark recognition and Barrett’s segment characterization. Proper identification of the gastroesophageal junction, diaphragmatic pinch and squamocolumnar junction is essential for reliable Prague classification and longitudinal surveillance consistency.

A major emphasis is placed on careful mucosal inspection using high-definition white light endoscopy combined with image-enhanced technologies. Modalities such as Narrow Band Imaging, blue light imaging and i-scan are highlighted as critical adjuncts for identifying subtle vascular and mucosal abnormalities associated with dysplasia.

The review additionally emphasizes the growing role of acetic acid chromoendoscopy, which can accentuate dysplastic mucosal patterns and improve targeted lesion recognition. This reflects the broader evolution of Barrett’s surveillance from random biopsy-driven protocols toward increasingly targeted optical diagnosis approaches.

Importantly, the article highlights that many dysplastic lesions in Barrett’s esophagus are extremely subtle and easily overlooked during rapid or low-quality examinations. Careful slow inspection, adequate mucosal cleansing and optimized insufflation are therefore fundamental components of high-quality surveillance.

The authors also stress adherence to systematic biopsy protocols following targeted lesion assessment. Although advanced imaging improves lesion detection, systematic four-quadrant biopsies remain important because flat dysplasia may still be endoscopically occult.

Clinically, the work reinforces that Barrett’s surveillance quality is operator dependent. Variability in withdrawal time, familiarity with dysplastic morphology and use of enhanced imaging likely contribute substantially to the persistently elevated post-endoscopy cancer rates observed in Barrett’s patients.

The review also aligns with increasing evidence supporting dedicated Barrett’s surveillance expertise and centralization of complex neoplasia management. High-quality surveillance requires not only technical proficiency but also advanced lesion recognition skills and familiarity with endoscopic resection strategies.

An important practical implication is the need for structured training in Barrett’s neoplasia recognition. As endoscopic eradication therapies increasingly replace surgery for early neoplasia, accurate detection and delineation of visible lesions become even more critical.

The article further reflects the broader movement within gastrointestinal endoscopy toward quality metric-driven practice. Similar to adenoma detection rates in colonoscopy, Barrett’s surveillance may increasingly adopt formal quality indicators including inspection time, adherence to biopsy protocols and use of advanced imaging.

From a therapeutic perspective, improved detection directly influences patient outcomes because early Barrett’s neoplasia can often be managed endoscopically using Endoscopic Mucosal Resection and ablative therapies, avoiding esophagectomy.

Overall, this review emphasizes that high-quality Barrett’s endoscopy requires a structured, meticulous and technology-enhanced approach. Careful landmark identification, prolonged mucosal inspection, advanced imaging utilization and systematic biopsy acquisition are central to reducing missed dysplasia and improving early esophageal cancer detection in Barrett’s surveillance programs.